bri-cel (BAY 2413334)
Relapsed/Refractory Multiple Myeloma
Key Facts
About Bayer
Bayer AG's mission is 'Health for all, Hunger for none,' focusing on advancing healthcare and food security through science-led innovation. The company has achieved significant scale and diversification, most notably through the transformative acquisition of Monsanto, establishing a leading position in agricultural sciences. Its strategy centers on driving growth in its core pharmaceutical pipeline—particularly in oncology, cardiology, and cell & gene therapy—while navigating legacy legal challenges and optimizing its portfolio to enhance shareholder value and operational focus.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| TECVAYLI + DARZALEX FASPRO | Johnson and Johnson Innovative Medicine | Approved |
| HDP-101 | Heidelberg Pharma | Phase 1/2a |
| CT053 | CARsgen Therapeutics | Phase 1b/2 |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| ABBV-383 | AbbVie | Phase 1 |
| Blenrep (belantamab mafodotin) | GSK plc | Phase III |
| Ciltacabtagene autoleucel (Carvykti) | Genscript Biotech | Approved / Phase 3 |
| CAR-T Cell Therapy | Dr. Reddy's Laboratories | Discovery/Development |
| Anitocabtagene Autoleucel (anito-cel) | Arcellx | Phase 2 |